After the Federal Trade Commission released its report highlighting the “enormous power” pharmacy benefit managers have over drug pricing and access, agency Commissioner Melissa Holyoak, criticized the report and its findings in a dissenting statement.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
